EFFICACY OF LIPID-LOWERING THERAPY IN COMBINATION WITH EZETIMIBE IN PATIENTS WITH CORONARY HEART DISEASE AND RENAL DYSFUNCTION
Keywords:
ezetimibe, statin, dyslipidemia, coronary heart disease, renal dysfunction, LDL-C, cardiovascular risk.Abstract
Coronary heart disease (CHD) remains a leading cause of morbidity and mortality worldwide, especially in patients with comorbid renal dysfunction. Dyslipidemia is a major modifiable risk factor in both conditions, and effective lipid-lowering therapy is essential to reduce cardiovascular events. This article reviews the clinical efficacy and safety of combination therapy using statins and ezetimibe in patients with CHD and impaired renal function. The article discusses the pharmacological rationale, current evidence from clinical trials, renal-specific lipid targets, and the potential of ezetimibe to optimize lipid control without exacerbating renal impairment. Special attention is given to the impact of combination therapy on LDL-C reduction, inflammation, and long-term cardiovascular outcomes in this high-risk population.
References
Cannon, C. P., et al. (2015). Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine, 372(25), 2387–2397.
Baigent, C., et al. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (SHARP): A randomised placebo-controlled trial. Lancet, 377(9784), 2181–2192.
Tonelli, M., & Wanner, C. (2019). Lipid management in chronic kidney disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2013 Clinical Practice Guideline. Annals of Internal Medicine, 160(3), 182–189.
Bays, H. E., et al. (2014). Ezetimibe: Clinical update on the mechanism of action and recent clinical trials. Clinical Lipidology, 9(4), 399–412.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
